Last edition
News about Global Pharma
Hengrui Pharma Grants Braveheart Bio Exclusive Global Rights to Cardiac Myosin Inhibitor HRS-1893
Hengrui Pharma has signed an exclusive licensing deal with US-based Braveheart Bio for its Phase 3-ready cardiac myosin inhibitor HRS-1893. Braveheart will make an upfront payment of USD 65 million and a near-term payment of up to USD 10 million upon technology transfer completion, totalling USD 75 million.
Global Pharma | 06/09/2025 | By Mrinmoy Dey | 576
Clearpoint Prism Neuro Laser Therapy System Receives FDA Clearance for 1.5T MRI Use
ClearPoint Neuro has announced that its ClearPoint Prism Neuro Laser Therapy System has received 510(k) clearance from the US FDA for use under 1.5T MRI guidance, in addition to its previously cleared 3T MRI compatibility.
Global Pharma | 06/09/2025 | By Dineshwori | 459
Cipla launches HUENA, maiden non-antibiotic drug in India for recurring UTIs
With HUENA, Cipla becomes the first in India to offer Methenamine Hippurate, a non-antibiotic therapy for recurrent UTIs, strengthening its fight against AMR.
Global Pharma | 06/09/2025 | By Dineshwori | 156
Arrowhead and Novartis Sign Global License and Collaboration Deal
Novartis secures exclusive global rights to Arrowhead’s ARO-SNCA therapy for Parkinson’s and related disorders, with Arrowhead receiving USD 200 million upfront.
Global Pharma | 05/09/2025 | By Dineshwori | 257
Argo Biopharma and Novartis Partner on Novel Cardiovascular Therapies
Argo to receive $160 million upfront as Novartis licenses pipeline assets, explores ANGPTL3 in dyslipidemia, and secures options for future siRNA candidates.
Global Pharma | 05/09/2025 | By Dineshwori | 369
Syantra, Inc., a cancer diagnostics innovator, has launched a new therapeutic division aimed at developing first-in-class immuno-oncology therapies to reprogram tumour-affected immune cells and restore anti-cancer immunity.
Global Pharma | 05/09/2025 | By Mrinmoy Dey | 132
Zydus and Synthon Sign Exclusive Licensing and Supply Agreement for Ozanimod Capsules for US Market
Zydus Lifesciences’ subsidiary Zydus Lifesciences Global FZE has signed an exclusive licensing and supply deal with Synthon BV to commercialise generic Ozanimod Capsules (ZEPOSIA) in the US market.
Global Pharma | 05/09/2025 | By Mrinmoy Dey | 210
NAYA Therapeutics Partners with Atley Solutions on Astatine-211 Radio Pharmaceuticals
NAYA Therapeutics will leverage Atley’s clinical manufacturing network and establish additional GMP sites using the Atley C100 for the final clinical-dose manufacturing of 211 At Targeted Alpha Therapies.
Global Pharma | 04/09/2025 | By Dineshwori | 419
Cayman Chemical, Curapath Join Forces to Expand Access to PEG-Free Shielding Lipids for LNPs
Cayman Chemical and Curapath have partnered to make PEG-free shielding lipids available to researchers advancing LNPs for non-viral drug delivery, gene therapy, mRNA vaccines, and biologic therapies.
Global Pharma | 04/09/2025 | By Mrinmoy Dey | 250
Lupin Secures US FDA Approval for Risperidone Long-Acting Injectable
Lupin has received US FDA approval for its Risperidone extended-release injectable suspension, marking the first product from its Nanomi long-acting injectables platform with 180-day CGT exclusivity.
Global Pharma | 03/09/2025 | By Mrinmoy Dey | 166
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy